Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Sex Differences in Cognitive Performance in Multiple Sclerosis
Multiple Sclerosis
P10 - Poster Session 10 (5:30 PM-6:30 PM)
9-003
To investigate, the sex differences in cognitive performance in multiple sclerosis (MS) patients.

Although, there is some evidence showing worse cognitive functioning in male MS patients, the role of brain pathology in this context has been less studied.

This study included 1052 patients, with relapsing-remitting MS. Brain MRI and neuropsychological assessment with the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) was performed. We used logistic regression adjusted for age, Expanded Disability Status Scale (EDSS), education and depression.
Males had similar age (37.2±8.9 vs. 38.5±8.8), education (mean: 14.8±3.1 vs. 14.7±3.0) and EDSS (median: 2.0 vs. 2.0), but shorter disease duration (mean: 8.4±6.5 vs. 10.1±7.2) and lower level of depressive symptoms (mean: 6.2±6.5 vs. 7.9±7.4) than females. The prevalence of abnormal cognitive screening (≥1 abnormal [<1.5 SD] BICAMS subtest) was slightly higher in males (30%) than females (26%). Females had higher scores in the Symbol Digit Modalities Test (SDMT) (56±11.8 vs. 54±11.0; p<0.001) and the California Verbal Learning Test Second Edition (CVLT-II) (60±11.3 vs. 54±12.1; p<0.001), but not in the Brief Visuospatial Memory Test-Revised (BVMT-R) (27.2±6.7 vs. 27.8±6.2; p>0.05). Paradoxically, females evaluated their cognitive performance as being worse than males (16.6 vs 14.5, p<0.004). Males had higher T2 lesion volume (median: 1.9 vs 1.6; p=0.01), but the same brain parenchymal fraction (median: both 85.4; p>0.05) as females. Sex differences in cognitive performance (SDMT and CVLT-II) remained significant also after adjustment for lesion burden and brain atrophy. We did not find major differences in the strength of association between cognitive and MRI measures in males and females.

Male sex was associated with slightly worse verbal memory and information processing speed. Brain MRI measures did not explain the sex difference in cognitive performance. Male sex should be considered as a risk factor for cognitive dysfunction.
Authors/Disclosures
Tomas Uher
PRESENTER 		Tomas Uher has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Tomas Uher has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol myers. Tomas Uher has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Tomas Uher has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. The institution of Tomas Uher has received research support from Novartis.
Manuela Vaneckova Manuela Vaneckova has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis . Manuela Vaneckova has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Manuela Vaneckova has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Manuela Vaneckova has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. The institution of Manuela Vaneckova has received research support from Czech Ministry of Health project—grants NU 22-04-00193 . Manuela Vaneckova has received research support from Czech Ministry of Health project - RVO VFN 64165 . Manuela Vaneckova has received personal compensation in the range of $500-$4,999 for serving as a principal investigator with Czech Ministry of Health project—grants NU 22-04-00193 .
Jan Krasensky No disclosure on file
No disclosure on file
Eva Havrdova, MD (Neurologicka Klinika 1 LF UK) Dr. Havrdova has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Havrdova has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Havrdova has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Havrdova has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Havrdova has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Havrdova has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Havrdova has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi.
Dana Horakova Dana Horakova has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dana Horakova has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dana Horakova has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dana Horakova has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck.